Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis

Launched by ASSIUT UNIVERSITY · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a specific protein called USP35 and its role in detecting a type of cell death known as ferroptosis in children with autoimmune hepatitis, a condition where the body's immune system mistakenly attacks the liver. The study aims to understand how the expression of USP35 relates to liver damage and inflammation in these patients. By comparing tissue samples from children with autoimmune hepatitis to those without the condition, researchers hope to learn more about the disease and how it affects the liver.

To participate in this trial, children aged from one day to 18 years who have been diagnosed with juvenile autoimmune hepatitis may be eligible. However, children with viral hepatitis or those over 18 years old cannot take part. If selected, participants will have tissue samples analyzed, which may help provide insights into their condition and contribute to better understanding and treatment of juvenile autoimmune hepatitis in the future. This trial is currently not recruiting participants, but it represents an important step in research aimed at improving care for affected children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged between one day and 18 years (children)
• • patients diagnosed clinically and physically with juvenile autoimmune hepatitis including seronegative autoimmune hepatitis cases
• Exclusion Criteria:
• • 1. Cases with inadequate tissue in the paraffin block
• • 2. Children with viral hepatitis
• • 3. patients above the age of 18 years old